Quarterly report pursuant to Section 13 or 15(d)

Reconciliation of IFRS Disclosure to US GAAP Disclosure

v3.21.2
Reconciliation of IFRS Disclosure to US GAAP Disclosure
3 Months Ended
Nov. 30, 2019
Reconciliation Of Ifrs Disclosure To Us Gaap Disclosure [Abstract]
RECONCILIATION OF IFRS DISCLOSURE TO US GAAP DISCLOSURE
28. RECONCILIATION OF IFRS DISCLOSURE TO US GAAP DISCLOSURE

The Company’s primary listing is on the TSX Venture Exchange (“TSXV”). The consolidated financial statements filed on that exchange are now filed in terms of US GAAP. Previously the consolidated financial statements were filed in terms of International Financial Reporting Standards (“IFRS”) (Note 1).


The Company’s comparative consolidated financial statements were prepared using US GAAP, therefore a reconciliation of the comparative IFRS and US GAAP presentation was performed for the comparative period.


The main differences between IFRS and US GAAP are as follows:


For the three months ended November 30,
2018
Net loss and comprehensive loss in accordance with IFRS $ 6,272,456
Capital raising fee (1,018,085 )
Share-based compensation (325,265 )
Net loss and comprehensive loss in accordance with US GAAP $ 4,929,106

November 30,
2018
Total shareholders’ equity in accordance with IFRS $ 33,936,971
Components of share capital in accordance with IFRS
Share capital 81,495,274
Share option reserve 13,377,325
Share warrant reserve 4,783,244
99,655,843
Adjustment for:
Share-based compensation (325,265 )
Share capital in accordance with US GAAP 99,330,578
Shares to be issued in accordance with IFRS and US GAAP 2,522,106
Deficit in accordance with IFRS (68,240,978 )
Adjustment for:
Capital raising fee adjustment 1,018,085
Share-based compensation 325,265
Deficit in accordance with US GAAP (66,897,628 )
Shareholders equity in accordance with US GAAP $ 34,955,056

Share-based compensation


The Company granted certain directors, officers and consultants of the Company stock options with vesting terms attached thereto, 25% vested immediately and a further 25% per annum, will vest on the grant date of the stock options. These stock options were valued using a Black Scholes valuation.


Under IFRS share-based compensation paid to certain directors, consultants and employees were amortized over the vesting period of the stock option grant using a weighted average expense over the vesting period, including the immediately vesting stock options.


Under US GAAP, the stock options issued to consultants were expensed immediately and the stock options issued to directors and officers were amortized as follows; (i) the value of the 25% of the stock options that vested immediately were expensed immediately; (ii) the remaining value of the 75% of the stock options which vest equally on an annual basis are being expensed over the vesting period on a straight line basis.


This gave rise to a reduction in expense of $325,265 for the three months ended November 30, 2018.


Capital raising fees


the company incurred certain shared based compensation on convertible debt and certain letter of credit funding arrangements. The share-based compensation was initially expensed immediately under IFRS. In terms of US GAAP, the capital raising fee is directly attributable to the debt and is recorded as a discount against the debt and amortized over the life of the debt. The capital raising fee of $1,276,980 less the amortization of the debt discount of $258,895 reduced the loss for the three months ended November 30, 2018 by $1,018,085.